EUVIMEDAtrasti EUVIMED
CrossrefInformacijos kortelė

MRI use prior to prostate biopsy after guideline recommendation in Canada

Jacob Bennett, Tarana A. Mangukia, Eden Philips, Tarana Mangukia, Tark Patel, Parsa Babaei Zadeh, Melis Guer, Adam Kinnaird

Canadian Urological Association Journal · 2026-10-19 · 21 (2)

DOI: 10.5489/cuaj.9701 ↗
SantraukaBibliografiniai duomenys

Santrauka

Introduction: Implementation of magnetic resonance imaging (MRI) prior to a prostate biopsy has improved detection of clinically significant prostate cancer, while reducing overdiagnosis of low-risk disease. Accordingly, the Canadian Urological Association (CUA) updated its prostate screening guidelines to recommend MRI prior to prostate biopsy in biopsy-naive men in 2022. This study aims to assess real-world implementation of pre-biopsy MRI by urologists in accordance with CUA guidelines. Methods: We conducted a retrospective, observational cohort study of all men undergoing prostate biopsy from April 2022 to April 2024 in Edmonton, AB, Canada. Data was extracted from a province-wide electronic medical record. Inclusion criteria were biopsy-naive men with a prostate-specific antigen (PSA) ≤20 ng/ml. Statistical analysis completed using Chi-squared and two-proportioned z-tests. Results: A total of 2626 men underwent prostate biopsy during the study period and 1491 participants met the inclusion criteria; 1054 (71%) received MRI prior to biopsy, with a median wait time to MRI of 101 days (interquartile range [IQR] 30–164). Inclusion of MRI in the diagnostic pathway was significantly associated with a longer interval from initial urology consultation to prostate biopsy (208 vs. 52 days, p

Jūsų darbui tinkamos žinios.

Nuo nemokamos pradžios ir asmeninės literatūros paieškos iki viso Research Suite.

Peržiūrėti tarifus →

Ar įtraukti visi leidėjų pilnieji tekstai?

Ne. Bibliografiniai įrašai, santraukos ir pilnieji tekstai yra skirtingas turinys. Ar pilnasis tekstas prieinamas, priklauso nuo šaltinio, Open Access ir jūsų turimų licencijų. EUVIMED planas nepakeičia papildomų leidėjų teisių.

Peržiūrėti tarifus →